ストックスクリーナーアプリを入手
2.19
0.69%
0.015
アフターアワーズ：
2.18
-0.010
-0.46%
前日終値:
$2.175
開ける：
$2.15
24時間の取引高:
5.92M
Relative Volume:
1.09
時価総額：
$431.51M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-0.7766
EPS:
-2.82
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
-2.67%
1か月 パフォーマンス:
-9.13%
6か月 パフォーマンス:
-4.37%
1年 パフォーマンス:
-3.52%
1日の値動き範囲:
$2.12
$2.23
1週間の範囲:
$2.12
$2.54
52週間の値動き範囲:
$1.58
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.19 | 431.51M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Wellington Management Group LLP Acquires 241,512 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Analysts Offer Predictions for ESPR FY2024 Earnings - MarketBeat
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock - Investing.com India
Cantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - MSN
Esperion Therapeutics issues $100M in new convertible notes - Investing.com
Esperion Therapeutics issues $100M in new convertible notes By Investing.com - Investing.com UK
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Esperion secures $150 million loan and $100 million notes By Investing.com - Investing.com UK
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewswire
Esperion Secures $250M in Strategic Financing, Restructures 80% of Debt in Major Deal - StockTitan
Cantor Fitzgerald starts coverage on Esperion stock, highlights strong potential for NEXLETOL - Investing.com Canada
Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion announces $210M convertible debt financing - MSN
Esperion Therapeutics, Inc. announced that it expects to receive $42.5 million in funding - Marketscreener.com
Future of Heterozygous Familial Hypercholesterolemia Drug - openPR
Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Esperion Announces $210 Million Convertible Debt Financing - GlobeNewswire
Esperion Secures $210M Debt Restructuring Deal with Strategic Convertible Notes Offering - StockTitan
Esperion secures licensing deal for heart drugs in Israel By Investing.com - Investing.com Canada
Esperion Partners with Neopharm to Commercialize NEXLETOL® - GlobeNewswire
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET - The Bakersfield Californian
Esperion Therapeutics Expands Global Reach with New Israeli Licensing Deal for Cholesterol Drugs - StockTitan
Esperion stock soars to 52-week high, hits $3.81 By Investing.com - Investing.com Canada
Esperion stock soars to 52-week high, hits $3.81 - Investing.com
Will The Long Awaited Breakout For Esperion Therapeutics Hold? (NASDAQ:ESPR) - Seeking Alpha
Anson Funds Management LP Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpTime to Buy? - MarketBeat
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada - MSN
Parkman Healthcare Partners LLC Cuts Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports
Esperion stock soars to 52-week high of $3.41 amid robust gains - Investing.com Nigeria
Esperion seeks Health Canada approval for cholesterol drugs - Investing.com Canada
Esperion stock soars to 52-week high of $3.41 amid robust gains By Investing.com - Investing.com South Africa
Esperion seeks Health Canada approval for cholesterol drugs By Investing.com - Investing.com UK
Esperion Announces New Drug Submissions in Canada for - GlobeNewswire
Esperion Seeks Canadian Approval for Two Novel Cholesterol-Lowering Drugs | ESPR Stock News - StockTitan
FY2025 EPS Estimate for Esperion Therapeutics Cut by Analyst - MarketBeat
Wasatch Advisors LP Purchases 6,483,070 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7%What's Next? - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys 295,378 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright - MarketBeat
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan
Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa
Esperion's chief commercial officer sells shares worth $426 - Investing.com
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
Esperion Therapeutics Inc (ESPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Dec 17 '24 |
Sale |
2.43 |
2,234 |
5,426 |
160,121 |
| Koenig Sheldon L. | President and CEO |
Dec 17 '24 |
Sale |
2.47 |
12,447 |
30,694 |
739,819 |
1.61%
1.65%
大文字化:
|
ボリューム (24 時間):